Cargando…
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial
RATIONALE: CFTR (cystic fibrosis transmembrane conductance regulator) dysfunction is associated with mucus accumulation and worsening chronic obstructive pulmonary disease (COPD) symptoms. OBJECTIVES: The aim of this phase IIb dose-finding study was to compare a CFTR potentiator, icenticaftor (QBW25...
Autores principales: | Martinez, Fernando J., Criner, Gerard J., Gessner, Christian, Jandl, Margret, Scherbovsky, Fernando, Shinkai, Masaharu, Siler, Thomas M., Vogelmeier, Claus F., Voves, Robert, Wedzicha, Jadwiga A., Bartels, Christian, Bottoli, Ivan, Byiers, Stuart, Cardenas, Pamela, Eckert, Joerg H., Gutzwiller, Florian S., Knorr, Barbara, Kothari, Mahavir, Parlikar, Rutvick, Tanase, Ana-Maria, Franssen, Frits M.E. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
American Thoracic Society
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10449083/ https://www.ncbi.nlm.nih.gov/pubmed/37411039 http://dx.doi.org/10.1164/rccm.202303-0458OC |
Ejemplares similares
-
Safety and efficacy of the cystic fibrosis transmembrane conductance regulator potentiator icenticaftor (QBW251)
por: Kazani, Shamsah, et al.
Publicado: (2021) -
Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD: Results from a Phase 2 Randomized Trial
por: Rowe, Steven M, et al.
Publicado: (2020) -
Icenticaftor, Novel Therapy for COPD: This Glass Is Half Full
por: Rennard, Stephen I.
Publicado: (2023) -
Differential Diagnosis of Suspected Chronic Obstructive Pulmonary Disease Exacerbations in the Acute Care Setting: Best Practice
por: Celli, Bartolome R., et al.
Publicado: (2023) -
CFTR mutations altering CFTR fragmentation
por: Tosoni, Kendra, et al.
Publicado: (2012)